SpringWorks Therapeutics Inc (NAS:SWTX)
$ 36.12 -0.08 (-0.22%) Market Cap: 2.68 Bil Enterprise Value: 2.25 Bil PE Ratio: 0 PB Ratio: 4.71 GF Score: 40/100

SpringWorks Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 08, 2021 / 07:00PM GMT
Release Date Price: $85.55 (+1.18%)
Corinne Jenkins
Goldman Sachs Group, Inc., Research Division - Research Analyst

Good afternoon, everyone. We are excited to welcome the team from SpringWorks here for the 42nd Annual Goldman Healthcare Conference.

Maybe just to kick it off, I'm going to turn it over to Saqib to give us an overview of SpringWorks and what they're up to these days?

Saqib Islam
SpringWorks Therapeutics, Inc. - CEO & Director

Great. Thank you so much, Corinne, and thank you to the team at Goldman for having us once again at the conference. If we can just turn to, I think we have 1 slide here that we're going to go through that essentially lays out the 3 different segments in oncology, in which we are active. We've got 12 different clinical programs ongoing in these 3 areas. And the span is relatively broad, and we've got data that's emergent in each of these areas over the course of 2021.

First, in late-stage trial in oncology, where we've got our DeFi study, Phase III top line data expected in the back half of this year. We have our MEK inhibitor that we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot